Author:
Zou Ting,Yin Jiye,Zheng Wei,Xiao Ling,Tan Liming,Chen Juan,Wang Ying,Li Xiangping,Qian Chenyue,Cui Jiajia,Zhang Wei,Zhou Honghao,Liu Zhaoqian
Funder
Open Foundation of Innovative Platform in University of Hunan Province of China
Hunan Provincial Science and Technology Plan of China
National High-tech R&D Program of China (863 Program)
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference40 articles.
1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29
2. Zhang T, Li J, Xia T, Zhang N, Zhang Y, Zhao J (2015) Association between COX-2 polymorphisms and non-small cell lung cancer susceptibility. Int J Clin Exp Pathol 8(3):3168–3173
3. Boolell V, Alamgeer M, Watkins DN, Ganju V (2015) The evolution of therapies in non-small cell lung cancer. Cancers 7(3):1815–1846
4. Cortes-Funes H, Martin C, Abratt R, Lund B (1997) Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anticancer Drugs 8(6):582–587
5. Han B, Guo Z, Ma Y, Kang S, Wang Y, Wei Q, Wu X (2015) Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy. Int J Clin Exp Pathol 8(4):4113–4119
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献